Developmental Reserach Pilot Projects

发展研究试点项目

• 批准号: 9149473
• 负责人: WILLIAM A CLIBY
• 金额: $ 9.52万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9149473
• 关键词: Address; Advisory Committees; Award; Cancer Patient; Chicago; Clinic; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Creativeness; Data; Development; Direct Costs; Disabled Persons; Disease; Facilities and Administrative Costs; Fostering; Foundations; Funding; Goals; Grant; Human Resources; Individual; Innovative Therapy; Institution; Intervention; Laboratories; Letters; Malignant neoplasm of ovary; Mayo Clinic Cancer Center; Measures; Minnesota; Minority; Monitor; Ovarian; Peer Review; Pharmaceutical Preparations; Pilot Projects; Platinum; Policies; Population; Principal Investigator; Process; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Resistance; Selection Criteria; Stimulus; System; Testing; Time; TimeLine; Translating; Translational Research; Uncertainty; United States National Institutes of Health; Universities; Woman; Work; Writing; anticancer research; base; cancer research center director; clinically relevant; experience; flavopiridol; improved; innovation; interdisciplinary collaboration; interest; originality; programs; sound; success

ABSTRACT – Developmental Research Program The goal of the Developmental Research Program (DRP) in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant interventions that will reduce the burden of ovarian cancer. This program was highly successful over the last 5 years, with support going to 30 pilot projects, twelve of which have received additional funding outside of the SPORE based on their pilot project, two that were awarded a second year of funding, one that advanced to a full project within the first funding period, and six that provided data instrumental for the selection of the major research projects in this renewal. This relatively junior program, having received only 58 months of funding at the time of this writing, has 37 associated publications and 10 associated clinical trials. We will build on the success of our first funding period, which attracted investigators new to ovarian cancer research who ultimately became Principal Investigators of projects included in this SPORE application or were awarded NIH funding outside of the SPORE. The DRP will 1) foster innovative laboratory, population, and clinical study proposals that have strong translational potential; 2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The DRP will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support at least four meritorious projects with $50,000 to be used within one year. In the first five years of our SPORE, we generated $990K direct dollars of institutional/Foundation support, approximately double the $500K proposed in the application for this time period; we will continue to seek additional support for ovarian cancer research in the years to come. Depending on the progress of a given project, there will be the possibility of a second year of support after competitive review of both new and continuation projects. The DRP will utilize a defined process to call for applications on an annual basis and to review submissions, utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translational potential, qualifications of the key personnel, and interactivity. As experienced in our first funding period, it is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in existing SPORE-sponsored projects or through peer-reviewed external grant support.

摘要 - 发展研究计划 卵巢癌蛋黄酱孢子中发展研究计划（DRP）的目标是 支持创新的，科学上合理的研究项目，从中可以将研究结果转化为临床 相关干预措施将减少卵巢癌的燃烧。这个程序非常成功 最近5年，支持30个试点项目，其中十二个已获得额外的资金 根据他们的飞行员项目，在孢子之外，两个被授予了第二年的资金，其中一个是 在第一个资金期内提前到一个完整的项目，六个为数据提供了工具 在此续签中选择主要的研究项目。这个相对初级计划，仅收到58 在撰写本文时，数月的资金有37个相关出版物和10项相关临床试验。 我们将基于我们的第一个资金时期的成功，这吸引了刚新的卵巢癌的调查员 最终成为此孢子应用中包括的项目的主要研究人员或 在孢子以外获得了NIH资金。 DRP将1）培养创新的实验室，人口和 具有强大翻译潜力的临床研究建议； 2）鼓励和支持跨学科 卵巢癌翻译研究的合作； 3）生成可以在 大规模的研究项目或卵巢癌的临床试验。 DRP每年将提供200,000美元 （孢子的$ 100,000，来自梅奥的$ 100,000）至少支持四个有功项目 一年内将使用50,000美元。在孢子的头五年中，我们直接产生了$ 990k 资金的机构/基金会支持，大约是申请中提议的50万美元的两倍 时间段；在未来的几年中，我们将继续为卵巢癌研究寻求更多支持。 根据给定项目的进度，将有可能获得第二年的支持 对新项目和延续项目的竞争评论。 DRP将利用一个定义的过程来呼吁 使用内部科学的专业知识，每年申请并审查提交 咨询委员会和其他经验丰富的调查员。选择标准将包括： 这项工作可能会影响卵巢癌，科学功绩，独创性，翻译的可能性 潜力，关键人员的资格以及互动性。正如我们在我们的第一个资金时期所经验的那样，这是 预计通过该计划对飞行员项目的支持将产生可以成为的新假设 在现有的孢子赞助的项目或通过同行评审的外部赠款支持中解决。